MAY 26, 2017 10:49 AM PDT

FDA Approved Cancer Drug Based on Mutation, Not Location

WRITTEN BY: Xuan Pham

For the first time, the US FDA approved a cancer drug for patients based on presence of genetic biomarkers. Whereas cancer drugs have been traditionally been approved based on the location of the tumor, Keytruda (pembrolizumab) is approved for cancer patients with genetic defects classified as “microsatellite instability” or “mismatch repair” deficiencies.

"KEYTRUDA binds to the PD-­1 receptor and blocks its interaction with PD-­L1 and PD-­L2, which helps restore the immune response." - Keytruda.com

"This is an important first for the cancer community," said Richard Pazdur, acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research and director of the FDA's Oncology Center of Excellence. "Until now, the FDA has approved cancer treatments based on where in the body the cancer started - for example, lung or breast cancers. We have now approved a drug based on a tumor's biomarker without regard to the tumor's original location."

Keytruda is a humanized antibody that works as a second-line immunotherapy agent to destroy the cancer. This drug targets the programmed cell death 1 (PD-1) receptor, a protein that’s responsible for preventing the immune system from attacking its own cells. Cancers can take advantage of this system by making its own proteins that bind to PD-1, which shuts down the body’s ability to kill the cancer. As an immunotherapy, pembrolizumab boosts the body’s ability to kill the cancer again. The drug is already approved for the treatment of several types of cancer, including non-small cell lung cancer, melanoma, and some head and neck cancers, and even mesothelioma.

But the new approval could significantly expand uses of this drug. In particular, Keytruda may now be used to treat any solid tumor as long as the patients have the indicated biomarkers: microsatellite instability-high (MSI-H) or mismatch-repair deficient (dMMR). These types of deficiencies are estimated to be present in about 4 percent of cancers, including colorectal, endometrial, and gastrointestinal cancers.

Notably, the drug’s new indication would expand access to cancer patients with solid tumors that have progressed despite treatment and for which there are no other therapy. For colorectal cancer, this means patients who have exhausted their chemotherapy defenses with drugs such as fluoropyrimidine, oxaliplatin, and irinotecan, Keytruda can be a new option.

“The FDA’s approval of this new indication for Keytruda further supports Merck’s commitment to helping people with difficult-to-treat cancers,” said Roger M. Perlmutter, president of Merck Research Laboratories, the drug’s manufacturer.

 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
MAY 14, 2020
Clinical & Molecular DX
New Tech Has Its AI on Brain Tumors
MAY 14, 2020
New Tech Has Its AI on Brain Tumors
  A collaboration across 29 research and healthcare agencies is putting together the world’s largest brain tu ...
MAY 13, 2020
Cancer
What role does geography play in childhood cancer?
MAY 13, 2020
What role does geography play in childhood cancer?
Research published in the International Journal of Health Geographics aims to explain the role that geography plays in p ...
MAY 25, 2020
Genetics & Genomics
FDA Approves the First Treatment for Neurofibromatosis 1
MAY 25, 2020
FDA Approves the First Treatment for Neurofibromatosis 1
In a major breakthrough, the Food and Drug Administration has approved a treatment for a genetic disorder called neurofi ...
JUN 01, 2020
Cancer
A New RNA in Fine-Tuned Signal Regulation
JUN 01, 2020
A New RNA in Fine-Tuned Signal Regulation
In a healthy cell, many complex networks work to make sure everything runs as it should. Some of these networks function ...
JUN 15, 2020
Cancer
New treatment for malignant pleural mesothelioma
JUN 15, 2020
New treatment for malignant pleural mesothelioma
New research reported during a virtual presentation of the Society of Interventional Radiology's 2020 Annual Scienti ...
JUL 11, 2020
Cancer
New drug combo could improve immunotherapy for SCCOHT ovarian cancer
JUL 11, 2020
New drug combo could improve immunotherapy for SCCOHT ovarian cancer
Research published recently in PLOS ONE reports on SP-2577, a drug that could help girls and young women plagued with a ...
Loading Comments...